# DefEYE Launches as Independent Ophthalmic Biologics Company with ExSight Ventures Seed Investment

> news · REPORTED · 2026-01-07

DefEYE, Inc. officially launched as an independent entity in early January 2026 after separating from Verséa Ophthalmics, holding exclusive rights to the BIOVANCE franchise of decellularized basement membrane products for ocular surface disease and surgery. In November 2025, ExSight Ventures provided seed funding to accelerate commercialization and expansion of its placental tissue solutions for eye care.

About DefEYE Inc: DefEYE, Inc. is a privately held Sarasota-based ophthalmic biologics company commercializing decellularized placental basement membrane grafts, including BIOVANCE and BIOVANCE 3L Ocular, for ocular surface diseases, pterygium surgery, and other ophthalmic surgical applications.

- Company: DefEYE
- Sector: medical devices
- Primary source: https://ophthalmology360.com/cornea-and-external-disease/defeye-inc-launches-as-independent-ophthalmic-biologics-company/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.